不同降温水平对院外心脏骤停昏迷幸存者效果的多中心随机先导试验:FROST-I试验
该多中心先导试验将院外心脏骤停(有目击、初始可除颤心律)昏迷幸存者1:1:1随机分至32°C(n=52)、33°C(n=49)、34°C(n=49),通过血管内降温装置维持24小时。主要终点为90天改良Rankin量表(mRS)≤3的存活比例,三组分别为65.3%、65.9%、65.9%,无统计学显著差异。多因素Cox模型显示男性性别和旁观者除颤与主要结局显著相关。90天前死亡的43例中28例死于撤除生命维持治疗,三组分别为7/16(43.8%)、10/13(76.9%)、11/14(78.6%),趋势检验p=0.04。所有降温水平耐受良好。作者认为未来研究应探索32°C目标温度管理的疗效。
要点
- 院外心脏骤停昏迷幸存者中,32°C(n=52)、33°C(n=49)、34°C(n=49)三组90天mRS≤3存活率分别为65.3%、65.9%、65.9%,无统计学显著差异。
- 多因素Cox比例风险模型识别出男性性别和旁观者除颤两个变量与主要结局显著相关。
- 90天前死亡43例中28例死于撤除生命维持治疗,32°C组7/16(43.8%)、33°C组10/13(76.9%)、34°C组11/14(78.6%),趋势检验p=0.04。
- 所有降温水平均耐受良好。
- 作者认为未来研究应探索32°C目标温度管理的疗效。
适用人群与场景
- 有目击的院外心脏骤停且初始心律为可除颤心律的昏迷幸存者。
诊断标准与关键阈值
- 主要终点为90天改良Rankin量表(mRS)评分≤3的存活比例,由盲法评估。
处置流程与药物剂量
- 通过血管内降温装置在24小时期间维持目标温度32°C、33°C或34°C。
研究设计与关键结果
- 多中心先导试验,1:1:1随机分至32°C(n=52)、33°C(n=49)、34°C(n=49)。
- 基线时旁观者实施除颤的比例在32°C组为13.5%、33°C组为34.7%、34°C组为28.6%(p=0.03)。
- 90天mRS≤3的存活比例(主要终点)在32°C、33°C、34°C组分别为65.3%、65.9%、65.9%,无统计学显著差异。
- 多因素Cox比例风险模型识别出两个与主要结局显著相关的变量:男性性别和旁观者除颤。
- 90天前死亡的43例患者中,28例死于撤除生命维持治疗,32°C组7/16(43.8%)、33°C组10/13(76.9%)、34°C组11/14(78.6%),趋势检验p=0.04。
- 所有降温水平均耐受良好。
证据类型、等级与局限
- 证据类型:多中心随机先导试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为未来研究应探索32°C目标温度管理的疗效。
- 原文未据此给出其他推荐。
指南或共识出处
- FROST-I试验(ClinicalTrials.gov标识号:NCT02035839)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To obtain initial data on the effect of different levels of targeted temperature management (TTM) in out-of-hospital cardiac arrest (OHCA).
METHODS: We designed a multicentre pilot trial with 1:1:1 randomization to either 32 °C (n = 52), 33 °C (n = 49) or 34 °C (n = 49), via endovascular cooling devices during a 24-h period in comatose survivors of witnessed OHCA and initial shockable rhythm. The primary endpoint was the percentage of subjects surviving with good neurologic outcome defined by a modified Rankin Scale (mRS) score of ≤ 3, blindly assessed at 90 days.
RESULTS: At baseline, different proportions of patients who had received defibrillation administered by a bystander were assigned to groups of 32 °C (13.5%), 33 °C (34.7%) and 34 °C (28.6%; p = 0.03). The percentage of patients with an mRS ≤ 3 at 90 days (primary endpoint) was 65.3, 65.9 and 65.9% in patients assigned to 32, 33 and 34 °C, respectively, non-significant (NS). The multivariate Cox proportional hazards model identified two variables significantly related to the primary outcome: male gender and defibrillation by a bystander. Among the 43 patients who died before 90 days, 28 died following withdrawal of life-sustaining therapy, as follows: 7/16 (43.8%), 10/13 (76.9%) and 11/14 (78.6%) of patients assigned to 32, 33 and 34 °C, respectively (trend test p = 0.04). All levels of cooling were well tolerated.
CONCLUSIONS: There were no statistically significant differences in neurological outcomes among the different levels of TTM. However, future research should explore the efficacy of TTM at 32 °C.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov unique identifier: NCT02035839 ( http://clinicaltrials.gov ).
参考来源
- Lopez-de-Sa E, Juarez M, Armada E, et al. A multicentre randomized pilot trial on the effectiveness of different levels of cooling in comatose survivors of out-of-hospital cardiac arrest: the FROST-I trial. Intensive Care Med. 2018. PMID: 30343315. doi:10.1007/s00134-018-5256-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。